Ionis Pharma (IONS +20.31%) and Biogen (BIIB) announce Spinraza meets primary endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
ChemoCentryx (CCXI +8.72%) announces presentations of 'positive' results from the Phase II CLEAR and CLASSIC trials of CCX168 at Kidney Week and the ACR 2016 meeting
Versartis (VSAR +6.04%) presents safety, efficacy, and IGF-I data from somavaratan treatment in the combined Phase 2a and ongoing VISTA long-term safety study for pediatric GHD
Decliners on news:
InfuSystem (INFU -4.7%) concludes that various prior financial statements should no longer be relied upon
Gainers on earnings:
Amicus Therapeutics (FOLD +16.12%) misses by $0.02; updates anticipated milestones
FB интересная ситуация
Biggest point losers: TVIX 17.4(-4.8), HSNI 32.35(-3.65), GOLD 82.68(-3.21), BIS 37.69(-3.08), ALXN 126.18(-2.82), AEM 49.01(-2.67), FNV65.01(-2.38), WRK 44.35(-2), NEM 35.87(-1.93), RGLD 74.42(-1.4), PINC 28.91(-1.34), ABX 17.06(-1.22), LEXAV 43.87(-1.13), SQQQ 14.06(-1.09), SLW 22.77(-1.03), TLT 130.77(-0.97), EPAM 60.78(-0.95), AU 13.29(-0.89), LXFT 49.3(-0.85), TMH 41.83(-0.83), USLV 18(-0.8), SBGL 10.9(-0.77), UGLD 11.74(-0.71), GG 14.61(-0.7), SA 10.68(-0.68)
- Ionis Pharma (IONS +20.31%) and Biogen (BIIB) announce Spinraza meets primary endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
- ChemoCentryx (CCXI +8.72%) announces presentations of 'positive' results from the Phase II CLEAR and CLASSIC trials of CCX168 at Kidney Week and the ACR 2016 meeting
- Versartis (VSAR +6.04%) presents safety, efficacy, and IGF-I data from somavaratan treatment in the combined Phase 2a and ongoing VISTA long-term safety study for pediatric GHD
Decliners on news:- InfuSystem (INFU -4.7%) concludes that various prior financial statements should no longer be relied upon
Gainers on earnings:- Amicus Therapeutics (FOLD +16.12%) misses by $0.02; updates anticipated milestones
- Horizon Pharma (HZNP +15.55%) beats by $0.08, reports revs in-line; reaffirms FY16 revs guidance
- BioCryst Pharma (BCRX +11.51%) beats by $0.10, beats on revs; updates financial guidance & provides a corporate update
Decliners on earnings:- Concordia (CXRX -36.36%) misses by $0.33, misses on revs; suspends guidance
- Nobilis Health (HLTH -13.33%) misses by $0.10, beats on revs; reaffirms FY16 revs guidance
- Aurinia Pharma (AUPH -6.67%) misses by $0.06
Upgrades/Downgrades:Stocks that traded to 52 week lows: ALV, CBIO, CERU, CGI, CHMA, CLLS, CORE, CRME, CTG, CXRX, EGY, EPAM, ETRM, EYES, FALC, FES, GLRI, GSVC, HSNI, IMNP, INAP, KEP, LFVN, LIVN, MDRX, NAO, NDLS, NGG, NVO, NXEO, PINC, PLUG, PPP, PRXL, PULM, PZRX, QVCA, RELY, SEAC, SSH, SSW, STON, SYRX, TINY, TLOG, TNDM, VMEM, VOD, VRML